Research
ICAP’s Global COVID-19 Response Is Improving the Odds for Millions of People in Vulnerable Communities Around the World
“When COVID-19 emerged, we realized that we had to pivot to quickly mobilize the resources needed in order to respond to the urgent calls for assistance that we were receiving.” — Wafaa El-Sadr, ICAP Director Since the first evidence of the coronavirus pandemic...
(NPR) ICAP’s Jessica Justman Speaks to the Potential of Convalescent Plasma Treatment Therapies
ICAP’s Jessica Justman, MD, senior technical director, remains hopeful in the potential benefits of convalescent plasma as treatment for patients with COVID-19. She recently spoke to NPR on the role the treatment could play in the global pandemic response:...
New PrEP Study Shows Significant Results for HIV Prevention
Researchers from the HIV Prevention Trials Network (HPTN) announced today that the HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every eight weeks was superior to daily oral...